Home Chronic Kidney Disease Complement-Based Therapy in the Management of Antibody-Mediated Rejection

Complement-Based Therapy in the Management of Antibody-Mediated Rejection

Credits to the Source Link Obum
Complement-Based Therapy in the Management of Antibody-Mediated Rejection
    • Sellares J.
    • de Freitas D.G.
    • Mengel M.
    • et al.

    Understanding the causes of kidney transplant failure: the dominant role of antibody-mediated rejection and nonadherence.

    Am J Transpl. 2012; 12: 388-399

    • Einecke G.
    • Sis B.
    • Reeve J.
    • et al.

    Antibody-mediated microcirculation injury is the major cause of late kidney transplant failure.

    Am J Transpl. 2009; 9: 2520-2531

    • Lamb K.E.
    • Lodhi S.
    • Meier-Kriesche H.U.

    Long-term renal allograft survival in the United States: a critical reappraisal.

    Am J Transpl. 2011; 11: 450-462

    • Lefaucheur C.
    • Loupy A.
    • Hill G.S.
    • et al.

    Preexisting donor-specific HLA antibodies predict outcome in kidney transplantation.

    J Am Soc Nephrol. 2010; 21: 1398-1406

    • Haas M.
    • Loupy A.
    • Lefaucheur C.
    • et al.

    The Banff 2017 Kidney Meeting Report: revised diagnostic criteria for chronic active T cell-mediated rejection, antibody-mediated rejection, and prospects for integrative endpoints for next-generation clinical trials.

    Am J Transpl. 2018; 18: 293-307

  • Significance of the positive crossmatch test in kidney transplantation.

    N Engl J Med. 1969; 280: 735-739

    • Montgomery R.A.
    • Loupy A.
    • Segev D.L.

    Antibody-mediated rejection: new approaches in prevention and management.

    Am J Transpl. 2018; 18: 3-17

    • Thurman J.M.
    • Panzer S.E.
    • Le Quintrec M.

    The role of complement in antibody mediated transplant rejection.

    Mol Immunol. 2019; 112: 240-246

    • Correa R.R.
    • Machado J.R.
    • da Silva M.V.
    • et al.

    The importance of C4d in biopsies of kidney transplant recipients.

    Clin Dev Immunol. 2013; 2013: 678180

    • Orandi B.J.
    • Alachkar N.
    • Kraus E.S.
    • et al.

    Presentation and outcomes of C4d-negative antibody-mediated rejection after kidney transplantation.

    Am J Transpl. 2016; 16: 213-220

    • Loupy A.
    • Hill G.S.
    • Suberbielle C.
    • et al.

    Significance of C4d Banff scores in early protocol biopsies of kidney transplant recipients with preformed donor-specific antibodies (DSA).

    Am J Transpl. 2011; 11: 56-65

    • Eskandary F.
    • Wahrmann M.
    • Muhlbacher J.
    • Bohmig G.A.

    Complement inhibition as potential new therapy for antibody-mediated rejection.

    Transpl Int. 2016; 29: 392-402

    • Stegall M.D.
    • Diwan T.
    • Raghavaiah S.
    • et al.

    Terminal complement inhibition decreases antibody-mediated rejection in sensitized renal transplant recipients.

    Am J Transpl. 2011; 11: 2405-2413

    • Cornell L.D.
    • Schinstock C.A.
    • Gandhi M.J.
    • Kremers W.K.
    • Stegall M.D.

    Positive crossmatch kidney transplant recipients treated with eculizumab: outcomes beyond 1 year.

    Am J Transpl. 2015; 15: 1293-1302

    • West-Thielke P.
    • Progar K.
    • Campara M.
    • et al.

    Eculizumab for prevention of antibody-mediated rejection in blood group-incompatible renal transplantation.

    Transplant Proc. 2018; 50: 66-69

    • Marks W.H.
    • Mamode N.
    • Montgomery R.A.
    • et al.

    Safety and efficacy of eculizumab in the prevention of antibody-mediated rejection in living-donor kidney transplant recipients requiring desensitization therapy: a randomized trial.

    Am J Transpl. 2019; 19: 2876-2888

    • Glotz D.
    • Russ G.
    • Rostaing L.
    • et al.

    Safety and efficacy of eculizumab for the prevention of antibody-mediated rejection after deceased-donor kidney transplantation in patients with preformed donor-specific antibodies.

    Am J Transpl. 2019; 19: 2865-2875

    • Schinstock C.A.
    • Bentall A.J.
    • Smith B.H.
    • et al.

    Long-term outcomes of eculizumab-treated positive crossmatch recipients: allograft survival, histologic findings, and natural history of the donor-specific antibodies.

    Am J Transpl. 2019; 19: 1671-1683

    • Lefaucheur C.
    • Viglietti D.
    • Hidalgo L.G.
    • et al.

    Complement-activating anti-HLA antibodies in kidney transplantation: allograft gene expression profiling and response to treatment.

    J Am Soc Nephrol. 2018; 29: 620-635

    • Locke J.E.
    • Magro C.M.
    • Singer A.L.
    • et al.

    The use of antibody to complement protein C5 for salvage treatment of severe antibody-mediated rejection.

    Am J Transpl. 2009; 9: 231-235

    • Lonze B.E.
    • Singer A.L.
    • Montgomery R.A.

    Eculizumab and renal transplantation in a patient with CAPS.

    N Engl J Med. 2010; 362: 1744-1745

    • Biglarnia A.R.
    • Nilsson B.
    • Nilsson T.
    • et al.

    Prompt reversal of a severe complement activation by eculizumab in a patient undergoing intentional ABO-incompatible pancreas and kidney transplantation.

    Transpl Int. 2011; 24: e61-e66

    • Stewart Z.A.
    • Collins T.E.
    • Schlueter A.J.
    • et al.

    Case report: eculizumab rescue of severe accelerated antibody-mediated rejection after ABO-incompatible kidney transplant.

    Transpl Proc. 2012; 44: 3033-3036

    • Orandi B.J.
    • Zachary A.A.
    • Dagher N.N.
    • et al.

    Eculizumab and splenectomy as salvage therapy for severe antibody-mediated rejection after HLA-incompatible kidney transplantation.

    Transplantation. 2014; 98: 857-863

    • Burbach M.
    • Suberbielle C.
    • Brocheriou I.
    • et al.

    Report of the inefficacy of eculizumab in two cases of severe antibody-mediated rejection of renal grafts.

    Transplantation. 2014; 98: 1056-1059

    • Yelken B.
    • Arpali E.
    • Gorcin S.
    • et al.

    Eculizumab for treatment of refractory antibody-mediated rejection in kidney transplant patients: a single-center experience.

    Transpl Proc. 2015; 47: 1754-1759

    • Tran D.
    • Boucher A.
    • Collette S.
    • Payette A.
    • Royal V.
    • Senecal L.

    Eculizumab for the treatment of severe antibody-mediated rejection: A case report and review of the literature.

    Case Rep Transplant. 2016; 2016: 9874261

    • Smith B.
    • Kumar V.
    • Mompoint-Williams D.
    • et al.

    Dosing eculizumab for antibody-mediated rejection in kidney transplantation: a case report.

    Transpl Proc. 2016; 48: 3099-3105

    • Kulkarni S.
    • Kirkiles-Smith N.C.
    • Deng Y.H.
    • et al.

    Eculizumab therapy for chronic antibody-mediated injury in kidney transplant recipients: a pilot randomized controlled trial.

    Am J Transpl. 2017; 17: 682-691

    • Davis 3rd, A.E.
    • Lu F.
    • Mejia P.

    C1 inhibitor, a multi-functional serine protease inhibitor.

    Thromb Haemost. 2010; 104: 886-893

    • Vo A.A.
    • Zeevi A.
    • Choi J.
    • et al.

    A phase I/II placebo-controlled trial of C1-inhibitor for prevention of antibody-mediated rejection in HLA sensitized patients.

    Transplantation. 2015; 99: 299-308

    • Viglietti D.
    • Gosset C.
    • Loupy A.
    • et al.

    C1 inhibitor in acute antibody-mediated rejection nonresponsive to conventional therapy in kidney transplant recipients: a pilot study.

    Am J Transpl. 2016; 16: 1596-1603

    • Montgomery R.A.
    • Orandi B.J.
    • Racusen L.
    • et al.

    Plasma-derived C1 esterase inhibitor for acute antibody-mediated rejection following kidney transplantation: results of a randomized double-blind placebo-controlled pilot study.

    Am J Transpl. 2016; 16: 3468-3478

  • A multicenter study to evaluate the efficacy and safety of Cinryze® for the treatment of acute antibody-mediated rejection in participants with kidney transplant (NCT02547220).

    (Available at:) (Accessed December 15, 2019)

    • Hirohashi T.
    • Uehara S.
    • Chase C.M.
    • et al.

    Complement independent antibody-mediated endarteritis and transplant arteriopathy in mice.

    Am J Transpl. 2010; 10: 510-517

    • Loupy A.
    • Lefaucheur C.
    • Vernerey D.
    • et al.

    Complement-binding anti-HLA antibodies and kidney-allograft survival.

    N Engl J Med. 2013; 369: 1215-1226

    • Thomas K.A.
    • Valenzuela N.M.
    • Reed E.F.

    The perfect storm: HLA antibodies, complement, FcgammaRs, and endothelium in transplant rejection.

    Trends Mol Med. 2015; 21: 319-329

    • Lefaucheur C.
    • Viglietti D.
    • Bentlejewski C.
    • et al.

    IgG donor-specific anti-human HLA antibody subclasses and kidney allograft antibody-mediated injury.

    J Am Soc Nephrol. 2016; 27: 293-304

    • Bouquegneau A.
    • Loheac C.
    • Aubert O.
    • et al.

    Complement-activating donor-specific anti-HLA antibodies and solid organ transplant survival: a systematic review and meta-analysis.

    Plos Med. 2018; 15: e1002572

    • Schinstock C.A.
    • Sapir-Pichhadze R.
    • Naesens M.
    • et al.

    Banff survey on antibody-mediated rejection clinical practices in kidney transplantation: diagnostic misinterpretation has potential therapeutic implications.

    Am J Transpl. 2019; 19: 123-131

  • Source Link

    Related Posts

    Leave a Comment

    This website uses cookies to improve your experience. We will assume you are ok with this, but you can opt-out if you wish. Accept Read More

    %d bloggers like this: